Clinical Trials Logo

Clinical Trial Summary

Despite advances in the treatment of acute lymphoblastic leukemia, the prognosis in adults is still poor, largely due to the resistance of treatment at diagnosis or early relapse. Among the strategies associated with the treatment of Acute Lymphoblastic Leukemia is rehabilitation and physical medicine in order to improve the quality of life, body composition, fitness, strength and improve the attachment and acceptance of their treatment


Clinical Trial Description

Previous evidence had shown that among the beneficial effects of an exercise intervention in cancer is the reduction of adverse events associated with treatment, such as nausea and fatigue. Also, the overexpression of Interleukin-15 in cancer is related to a poor prognosis, biologically the implementation of a cross-training exercise routine can function as a regulatory pathway for its expression due to its consumption at muscular level. Finally, the time to consider a relapse with a very poor prognosis is during first three months of treatment, so implementation of an exercise strategy during this period could reduce the proportion of early relapses mediated by Interleukin-15 expression ;


Study Design


Related Conditions & MeSH terms


NCT number NCT05059847
Study type Interventional
Source Hospital General de Mexico
Contact Christian O Ramos Peñafiel, PhD
Phone +52 55 27892000
Email [email protected]
Status Recruiting
Phase N/A
Start date September 6, 2021
Completion date May 19, 2023

See also
  Status Clinical Trial Phase
Active, not recruiting NCT03709719 - Blinatumomab in High-risk B-cell Precursor Acute Lymphoblastic Leukemia Phase 2
Recruiting NCT04545333 - The clonoSEQ® Watch Registry
Completed NCT02975687 - CD19 CAR T Cells in Patients With Resistant or Refractory CD19+ Acute Lymphoblastic Leukemia Phase 1
Active, not recruiting NCT03984968 - CD19 CAR-T Consolidation Therapy for Acute Lymphoblastic Leukemia Phase 2